Picture of Exscientia logo

EXAI Exscientia Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid Cap

Momentum

Relative Strength (%)
1m-9.58%
3m-21.88%
6m-9.04%
1yr-36.48%
Volume Change (%)
10d/3m+75.69%
Price vs... (%)
52w High-38.81%
50d MA-4.01%
200d MA-8.57%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-39.46%
Return on Equity-36.34%
Operating Margin-714.07%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Exscientia EPS forecast chart

Profile Summary

Exscientia PLC is a drug design and development company. The Company combines precision design with integrated experimentation to invent and develop drugs. It uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. It uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. It has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. It combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The Company's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    June 30th, 2024
    Incorporated
    June 29th, 2021
    Public Since
    January 1st, 1970
    No. of Employees
    483
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Select Market
    Shares in Issue
    256,273,019

    EXAI Share Price Performance

    Upcoming Events for EXAI

    Q4 2024 Exscientia PLC Earnings Release

    Exscientia PLC Annual Shareholders Meeting

    Q1 2025 Exscientia PLC Earnings Release

    Similar to EXAI

    Picture of 2Seventy Bio logo

    2Seventy Bio

    us flag iconNASDAQ Global Select Market

    Picture of 4D Molecular Therapeutics logo

    4D Molecular Therapeutics

    us flag iconNASDAQ Global Select Market

    Picture of AbCellera Biologics logo

    AbCellera Biologics

    us flag iconNASDAQ Global Select Market

    Picture of AbSci logo

    AbSci

    us flag iconNASDAQ Global Select Market

    Picture of Acadia Pharmaceuticals logo

    Acadia Pharmaceuticals

    us flag iconNASDAQ Global Select Market

    FAQ